T Bachelot

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi request reprint Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells
    Robert Pawliuk
    Division of Health Sciences and Technology, Harvard MIT, Cambridge, Massachusetts 02139, USA
    Mol Ther 5:345-51. 2002
  2. ncbi request reprint Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer
    Etienne G C Brain
    Department of Medical Oncology, René Huguenin Cancer Centre, Saint Cloud, France
    JAMA 293:2367-71. 2005
  3. pmc Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
    T Bachelot
    Centre Leon Berard, Equipe Cytokines et Cancer, INSERM U 590, 28 rue Laennec, 69008 Lyon, France
    Br J Cancer 94:1066-70. 2006
  4. pmc Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study
    François Clément Bidard
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Breast Cancer Res 14:R29. 2012
  5. pmc A candidate molecular signature associated with tamoxifen failure in primary breast cancer
    Julie A Vendrell
    Universite de Lyon, Faculté de Pharmacie de Lyon, France
    Breast Cancer Res 10:R88. 2008
  6. pmc Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
    Rhizlane Belbaraka
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, Lyon 69008, France
    BMC Res Notes 3:164. 2010
  7. pmc Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
    Philippe A Cassier
    Department of Medecine, Centre Leon Berard, Lyon, France
    BMC Cancer 11:213. 2011
  8. pmc Validation of prognostic scores for survival in cancer patients beyond first-line therapy
    Olivier Tredan
    Universite de Lyon, Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    BMC Cancer 11:95. 2011
  9. pmc Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer
    Philippe Leissner
    Oncology and Human Genetics Department, bioMerieux SA, Grenoble, F 38024, France
    BMC Cancer 6:216. 2006
  10. ncbi request reprint [Adjuvant therapies: the example of breast cancer]
    Thomas Bachelot
    Centre Leon Berard, 69008 Lyon
    Rev Prat 58:817-9. 2008

Detail Information

Publications58

  1. ncbi request reprint Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells
    Robert Pawliuk
    Division of Health Sciences and Technology, Harvard MIT, Cambridge, Massachusetts 02139, USA
    Mol Ther 5:345-51. 2002
    ..Resolution of this paradox may come from human trials of endostatin now underway...
  2. ncbi request reprint Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer
    Etienne G C Brain
    Department of Medical Oncology, René Huguenin Cancer Centre, Saint Cloud, France
    JAMA 293:2367-71. 2005
    ..Adjuvant chemotherapy with new cytotoxic agents for breast cancer must be properly assessed for toxicity...
  3. pmc Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
    T Bachelot
    Centre Leon Berard, Equipe Cytokines et Cancer, INSERM U 590, 28 rue Laennec, 69008 Lyon, France
    Br J Cancer 94:1066-70. 2006
    ..This could have important therapeutic implications with regard to endostatin therapy and raises the question of a possible role of this humoral reaction against endostatin in the neoplastic process...
  4. pmc Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study
    François Clément Bidard
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Breast Cancer Res 14:R29. 2012
    ..However, serum marker levels are also used for the same purpose, and no clear comparison has been reported to date...
  5. pmc A candidate molecular signature associated with tamoxifen failure in primary breast cancer
    Julie A Vendrell
    Universite de Lyon, Faculté de Pharmacie de Lyon, France
    Breast Cancer Res 10:R88. 2008
    ..Identification of such markers would be clinically useful. We attempted to identify molecular markers associated with tamoxifen failure in breast cancer...
  6. pmc Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
    Rhizlane Belbaraka
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, Lyon 69008, France
    BMC Res Notes 3:164. 2010
    ..In this prospective study, which included 45 patients, we identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line chemotherapy were identified...
  7. pmc Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
    Philippe A Cassier
    Department of Medecine, Centre Leon Berard, Lyon, France
    BMC Cancer 11:213. 2011
    ..Chemokines CCL19, CCL20 and CCL21 and their receptors CCR6 and CCR7, were assessed as potential biomarkers of metastatic dissemination in primary breast cancer...
  8. pmc Validation of prognostic scores for survival in cancer patients beyond first-line therapy
    Olivier Tredan
    Universite de Lyon, Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    BMC Cancer 11:95. 2011
    ..We aimed to validate prognostic scores for survival in patients undergoing chemotherapy for advanced or metastatic cancer after first-line treatment...
  9. pmc Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer
    Philippe Leissner
    Oncology and Human Genetics Department, bioMerieux SA, Grenoble, F 38024, France
    BMC Cancer 6:216. 2006
    ..In this study, we investigated the prognostic value of uPA and PAI-1 at the mRNA level in lymph node- and hormone receptor-positive breast cancer...
  10. ncbi request reprint [Adjuvant therapies: the example of breast cancer]
    Thomas Bachelot
    Centre Leon Berard, 69008 Lyon
    Rev Prat 58:817-9. 2008
    ..The development of national and regional therapeutic guidelines markedly diminished the arbitrary aspect of the decision. Developing tools which could help implying the patient in this therapeutic decision is a priority...
  11. pmc A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients
    T Bachelot
    Département de Cancérologie Médicale Centre Léon Bérard, 28 rue Laennec, 69373 Lyon Cedex, France
    Br J Cancer 87:1079-85. 2002
    ..Three patients were alive, free of disease 30 months after completion of the study. Such therapy allows for high-dose intensity and high cumulative doses on a short period of time with manageable toxicity...
  12. ncbi request reprint [Angiogenesis and breast cancer]
    Thomas Bachelot
    Centre Leon Berard, Departement de Medecine, 28, rue Laennec, 69373 Lyon Cedex 08
    Bull Cancer 94:S203-10. 2007
    ..This is a review of the major biological and clinical data available on the critical role of angiogenesis in breast cancer. We will also review the different clinical studies reported to date in this area...
  13. pmc Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
    T Bachelot
    Unité Cytokine et Cancer, INSERM U 453 and Centre Léon Bérard, 28 rue Laënnec 69008 Lyon, France
    Br J Cancer 88:1721-6. 2003
    ..Vascular endothelial growth factor serum and plasma levels are not useful indicators of prognosis for these patients...
  14. ncbi request reprint Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials
    T Bachelot
    Departement de cancerologie medicale, Centre Leon Berard, Lyon, France
    Ann Oncol 11:151-6. 2000
    ..This study was performed to identify prognostic variables for toxicity and survival in patients who participate in phase I clinical trials...
  15. ncbi request reprint [Clinical development of anti-angiogenic agents in 2002]
    Thomas Bachelot
    Unité Cytokines et Cancers, INSERM U453, Centre Leon Berard, 28, rue Laennec, 69373 Lyon Cedex 08
    Bull Cancer 90:19-23. 2003
    ..Further clinical trials are needed to gain clear insight into the precise role of those promising strategies for the management of solid tumours...
  16. doi request reprint Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer
    Thomas Bachelot
    Département de Cancérologie Médicale et Unité INSERM U590Centre Léon Bérard, 28 rue LaënnecFR 69373 Lyon Cedex 08, France
    Oncology 80:262-8. 2011
    ..To assess the efficacy of capecitabine plus docetaxel (XT) versus epirubicin plus docetaxel (ET) as first-line therapy for metastatic breast cancer (MBC)...
  17. ncbi request reprint Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    Cancer 82:134-40. 1998
    ..v.) infusion, and vinorelbine (VNB) was delivered at a dose of 6 mg i.v. bolus followed by VNB, 6 mg/m2/day, in continuous i.v. infusion (Days 1-5) every 21 days...
  18. ncbi request reprint Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer
    P Biron
    Centre Leon Berard, Lyon, France
    Bone Marrow Transplant 41:555-62. 2008
    ..8) and 22.9 versus 22.3 months median time to relapse in the intensification and observation arms, respectively. In this randomized trial, HDC with CHUT improved DFS but not OS, corroborating findings from earlier trials...
  19. ncbi request reprint The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group
    J Blay
    PARMA Cooperative Group with Fédération Nationale des Centres de Lutte Contre le Cancer FNCLCC, Dutch Haemato Oncology Working Party HOVON, European Organization for Research and Treatment of Cancer EORTC, Lyon, France
    Blood 92:3562-8. 1998
    ....
  20. doi request reprint Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis
    Bénédicte Poncet
    Département d information médicale, Unit of Medico Economic Evaluation, Hospices Civils de Lyon, Lyon, France
    Am J Clin Oncol 31:363-8. 2008
    ..This open controlled prospective study aimed at evaluating the medical and economical impact of first line chemotherapy for metastatic breast cancer (MBC)...
  21. pmc Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
    I Ray Coquard
    , Lyon, France
    Br J Cancer 85:816-22. 2001
    ..In conclusion, poor performance status and lymphopenia identify a subgroup of patients at high risk for early death after chemotherapy...
  22. doi request reprint Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer
    N Carrabin
    Centre Leon Berard, Department of Surgical Oncology, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 97:E23-32. 2010
    ..To assess the feasibility and efficacy of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) without adjuvant chemotherapy for relapsed or persistent advanced ovarian cancer...
  23. ncbi request reprint Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model
    E Jouanneau
    , , Lyon, France
    J Neurooncol 51:11-8. 2001
    ..The lack of correlation between serum concentration and tumor response raises concern regarding the mechanism of action of endostatin...
  24. doi request reprint A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer
    Philippe A Cassier
    Multidisciplinary Medical Oncology Day Unit, Edouard Herriot Hospital, Lyon, France
    Cancer 113:2532-8. 2008
    ..A study was conducted to determine the efficacy, tolerability, and safety of concurrent cisplatin and vinorelbine chemotherapy and radiotherapy in patients with previously untreated brain metastases from breast cancer...
  25. ncbi request reprint Breast cancer predictions by neural networks analysis: a comparison with logistic regression
    V S Bourdès
    Themis ICTA Group, Lyon, France
    Conf Proc IEEE Eng Med Biol Soc 2007:5424-7. 2007
    ....
  26. doi request reprint Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE
    C De la Fouchardiere
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Ann Oncol 20:1959-63. 2009
    ..This phase II study evaluated the clinical benefit of pegylated liposomal doxorubicin (PLD) and docetaxel (Taxotere) as first-line therapy for metastatic breast cancer (MBC)...
  27. doi request reprint Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series
    Sana Intidhar Labidi
    Department of Medical Oncology, Centre Leon Berard, Laennec, France
    Clin Breast Cancer 9:118-21. 2009
    ....
  28. ncbi request reprint [Are antiangiogenic antibodies universal for solid tumor?]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 94:S191-6. 2007
    ..This review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast, lung, and colorectal cancers...
  29. doi request reprint Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution
    Jerome Fayette
    Universite de Lyon, Centre Leon Berard, Lyon, France
    Anticancer Drugs 21:553-8. 2010
    ..2 months (95% CI: 5.2-8.8). Paclitaxel can be used in symptomatic patients. Although no improvement of overall survival can be expected, paclitaxel treatment is safe and achieves interesting response rates...
  30. doi request reprint Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer
    Francois Bertucci
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes IPC, Marseille, France
    Breast Cancer Res Treat 127:363-73. 2011
    ..Our predictor refines the prediction of metastasis-free survival after adjuvant anthracycline-based CT and might help tailoring adjuvant CT regimens...
  31. ncbi request reprint Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France
    Magali Morelle
    Health Economics Research Group in Oncology, Centre Leon Berard, Lyon, France
    Int J Technol Assess Health Care 22:396-401. 2006
    ..A cost-effectiveness analysis was conducted comparing diagnostic strategies for determining the HER2 status of invasive breast carcinomas, as an indication for trastuzumab at metastatic relapse...
  32. ncbi request reprint [Neoadjuvant chemotherapy and ovarian cancer]
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon
    Bull Cancer 93:669-76. 2006
    ..The strategy of neoadjuvant chemotherapy, followed by interval debulking surgery, should be confirmed in a prospective randomized trial. The EORTC55971 trial is currently addressing this issue...
  33. ncbi request reprint [Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials]
    Jean Paul Guastalla
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 91:S99-108. 2004
    ..Clinical trials are planed with the anti Cox2 celecoxib for breast cancer prevention, in adjuvant setting, in metastatic situation combined with exemestane or antitubulin drugs or in neoadjuvant therapy...
  34. doi request reprint Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge
    Catherine Sebban
    Centre Leon Berard, 28 rue Laennec, Lyon, France
    Support Care Cancer 16:1017-23. 2008
    ..Optimal management remains to be clearly defined, and new oral antibiotics need to be evaluated in this setting...
  35. ncbi request reprint [Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials]
    Jean Paul Guastalla
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 91:S99-108. 2004
    ..Clinical trials are planed with the anti Cox2 celecoxib for breast cancer prevention, in adjuvant setting, in metastatic situation combined with exemestane or antitubulin drugs or in neoadjuvant therapy...
  36. ncbi request reprint Elaborating patient information with patients themselves: lessons from a cancer treatment focus group
    Nora Moumjid
    GRESAC Research Group in Health Economics and Networks in Cancer Care, CNRS, UMR 5823, Centre Leon Berard, Comprehensive Cancer Centre and University Claude Bernard Lyon 1, Lyon, France
    Health Expect 6:128-39. 2003
    ..To assess the significance of patients' input in the elaboration of a patient information booklet...
  37. ncbi request reprint [Prognostic factors for febrile neutropenia]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 93:501-6. 2006
    ..Research in quantifying the risk of neutropenic complications may make it possible in the near future to target patients at greater risk with appropriate preventive strategies, thereby maximizing the benefits and minimizing the costs...
  38. ncbi request reprint Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008, Lyon, France
    Gynecol Oncol 88:351-7. 2003
    ..We have assessed the feasibility and evaluated the tolerance of epirubicin (EPI) combined with paclitaxel (TAX) in heavily pretreated ovarian cancer patients...
  39. doi request reprint A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group
    I Ray-Coquard
    Department of Medical Oncology, Léon Bérard Comprehensive Cancer Center, University of Lyon, and EA 4128 SIS Individu Santé, Société, Lyon, France
    Ann Oncol 20:1105-12. 2009
    ....
  40. pmc Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
    Isabelle Ray-Coquard
    Université de Lyon Centre Léon Bérard, Department of Medical Oncology and EA SIS 4128, Lyon, France
    Cancer Res 69:5383-91. 2009
    ..48; 95% CI, 1.03-2.1) along with IPI. Our findings show that lymphopenia is an independent prognostic factor for overall and progression-free survival in several cancers...
  41. ncbi request reprint [Spontaneous regression of breast cancer after biopsy. About two cases]
    L Maillet
    Centre Leon Berard, Departement de Chirurgie Oncologique, Universite de Lyon 1, 28, rue Laennec, 69008 Lyon, France
    Gynecol Obstet Fertil 42:269-72. 2014
    ..These cases illustrate a rare phenomenon. The main hypothesis is a carcinoma- directed immune response triggered by the biopsy. ..
  42. ncbi request reprint [Adjuvant therapy for breast cancer patients: treatment decision tree from a French cancer network]
    Thomas Bachelot
    Centre Leon Berard, 28, rue Laennec, 69373 Lyon Cedex 08, France
    Bull Cancer 89:897-903. 2002
    ..However, due to the subjectivity of risk/benefit estimations, patients themselves should become more involved in the decision-making process...
  43. ncbi request reprint Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma
    Line Claude
    Department of Radiation Oncology, Hopital Edouard Herriot, Lyon, France
    Radiother Oncol 76:334-9. 2005
    ..To determine overall survival (OS) and independent prognostic factors in patients with brain metastases (BM) from breast cancer treated by whole brain radiotherapy (WBR)...
  44. ncbi request reprint A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Philippe A Cassier
    Medical Oncology, Hopital Edouard Herriot, Université de Lyon et Hospices Civils de Lyon, Lyon, France
    Breast Cancer Res Treat 109:343-50. 2008
    ..In first-line metastatic breast cancer, both paclitaxel (P)-doxorubicin (A) and docetaxel (D)-doxorubicin (A) combinations have shown superiority over treatments without taxane. The aim of this study was to compare the two combinations...
  45. ncbi request reprint The role of angiogenesis in endocrine liver metastases: an experimental study
    Celine Pourreyron
    INSERM, U865, Faculte Laennec, Universite Claude Bernard Lyon 1, Lyon, France
    J Surg Res 144:64-73. 2008
    ..4 +/- 5.6% versus 18.3 +/- 3.4). Our results suggest that active angiogenesis is not necessary for the engraftment and early growth of endocrine cells metastatic to the liver but is required at a later stage of progression...
  46. pmc Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer
    Julien Fitamant
    Apoptosis, Cancer, and Development Laboratory Equipe Labellisée La Ligue, Centre National de la Recherche Scientifique, Unite Mixte de Recherche 5238, Centre Leon Berard, Université de Lyon 69008 Lyon, France
    Proc Natl Acad Sci U S A 105:4850-5. 2008
    ....
  47. ncbi request reprint [Anemia and chemotherapy]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 90:S133-43. 2003
    ..In addition, anemia could relieve of specific treatment such as blood transfusion or preventive treatment with recombinant erythropoietin...
  48. ncbi request reprint Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes
    Marie Cécile Thomachot
    Equipe Cytokines et Cancers, INSERM U 590, Centre Léon B, Lyon, France
    Int J Cancer 110:710-20. 2004
    ..The infiltration of BCC by these altered DC may contribute to the impaired immune response against the tumor...
  49. ncbi request reprint IL-6 as an intracrine growth factor for renal carcinoma cell lines
    Laurent Alberti
    Equipe Cytokine et Cancer, Unité Inserm 590, Lyon, France
    Int J Cancer 111:653-61. 2004
    ..IL-6 ASON inhibited the proliferation of the 8 RCC cell lines tested additively with IL-4 or IL-13. IL-6 is an intracrine growth factor in renal cell carcinoma cell lines...
  50. doi request reprint Body weight change in women receiving adjuvant chemotherapy for breast cancer: a French prospective study
    Olivier Tredan
    Université de Lyon Centre Léon Bérard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    Clin Nutr 29:187-91. 2010
    ..Adjuvant chemotherapy has frequently been associated with weight gain after breast cancer diagnosis. We aimed to prospectively evaluate body weight variations in French patients with early breast cancer...
  51. ncbi request reprint Development of a rule based prognostic tool for HER 2 positive breast cancer patients
    Paulo J G Lisboa
    School of Computing and Mathematical Sciences, Liverpool John Moores University, Liverpool, UK
    Conf Proc IEEE Eng Med Biol Soc 2007:5416-9. 2007
    ..The practical clinical value of this decision support tool will in future be tested by external validation with additional data from other clinical centres...
  52. ncbi request reprint Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia
    Wolfgang Eisterer
    Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, V5Z 1L3, Canada
    Mol Ther 5:352-9. 2002
    ....
  53. ncbi request reprint Dendritic cell infiltration and prognosis of early stage breast cancer
    Isabelle Treilleux
    Departments of Pathology, Medicine, Surgery, Radiotherapy and Radiology, and Equipe Cytokines et Cancers INSERM U590 Lyon, France
    Clin Cancer Res 10:7466-74. 2004
    ..Although dendritic cells (DC) and T cells can infiltrate primary breast carcinoma, it remains unclear whether the immune response influences the clinical outcome...
  54. ncbi request reprint [Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)]
    Catherine Lhomme
    Institut Gustave Roussy, Villejuif, France
    Bull Cancer 91:609-20. 2004
    ..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
  55. ncbi request reprint Breast cancer with synchronous metastases: trends in survival during a 14-year period
    Fabrice Andre
    Breast Cancer Unit, Comite 050, Institut Gustave Roussy, 39 Rue C Desmoulins, 94805 Villejuif, France
    J Clin Oncol 22:3302-8. 2004
    ..This study sought to determine whether survival has improved over time for breast cancer patients who had metastases at diagnosis...
  56. ncbi request reprint [Treatment of hot flashes in women with a previous diagnosis of breast cancer]
    Philippe Debourdeau
    Service de Medecine Interne, Hôpital Desgenettes, 108, boulevard Pinel, 69003 Lyon
    Bull Cancer 91:339-49. 2004
    ....
  57. ncbi request reprint [Adjuvant chemotherapy for breast cancer and targeted therapies]
    Armelle Dufresne
    Service d Oncologie Medicale, Hopital Edouard Herriot, Lyon
    Rev Prat 58:477-8. 2008
  58. doi request reprint Time-to-event analysis with artificial neural networks: an integrated analytical and rule-based study for breast cancer
    Paulo J G Lisboa
    School of Computing and Mathematical Sciences, Liverpool John Moores University, UK
    Neural Netw 21:414-26. 2008
    ..This paper extends the existing OSRE methodology to data sets that include continuous-valued variables...